Skip to main content

Table 4 Hemagglutination-inhibition antibody responses after TIV in the per-protocol immunogenicity cohort

From: A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine

Strain

Time point

Seropositive

GMT

MGI

n (%; 95% CI)

value (95% CI)

value (95% CI)

18–60 years

>60 years

18–60 years

>60 years

18–60 years

>60 years

N = 49

N = 70

N = 49

N = 70

N = 49

N = 70

A/H1N1

Day 0

35

37

39.2

15.2

(71.4; 56.7–83.4)

(52.9; 40.6–64.9)

(24.0–63.8)

(11.1–21.0)

Day 21

49

70

390.1

142.1

10.0 (6.3–15.7)

9.3 (6.8–12.8)

(100; 92.7–100)

(100; 94.9–100)

(293.8–518.1)

(105.1–192.0)

A/H3N2

Day 0

26

38

14.1

13.0

(53.1; 38.3–67.5)

(54.3; 41.9–66.3)

(10.1–19.8)

(9.8–17.3)

Day 21

49

70

185.6

183.7

13.1 (9.3–18.5)

14.1 (10.2–19.5)

(100; 92.7–100)

(100; 94.9–100)

(140.9–244.5)

(139.6–241.8)

B strain (Victoria)

Day 0

34

58

22.7

28.0

(69.4; 54.6–81.7)

(82.9; 72.0–90.8)

(15.2–34.0)

(21.5–36.5)

Day 21

48

69

260.6

248.6

11.5 (7.0–18.7)

8.9 (6.3–12.4)

(98.0; 89.1–99.9)

(98.6; 92.3–100)

(184.6–368.0)

(185.9–332.3)

  1. TIV, inactivated trivalent influenza vaccine; Seropositive, titer ≥1:10; GMT, geometric mean titer; MGI, mean geometric increase defined as the geometric mean of the ratio between pre-vaccination and post-vaccination reciprocal titers.